BOSTON, July 19, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on
the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it will host
a conference call and live audio webcast on Wednesday, August 2, 2017 at 8:30 AM ET to report second quarter 2017 financial results
and provide an update on its clinical development efforts for omadacycline for skin infections, community-acquired bacterial
pneumonia, and urinary tract infections.
The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at
www.paratekpharma.com.
Domestic investors wishing to participate in the call should dial: 877-407-0792 and international investors should dial:
201-689-8263. The conference ID is 13665445. Investors can also access the call at http://public.viavid.com/index.php?id=125152.
Replays of the call will be available through August 16, 2017. Domestic investors can access the replay by dialing 844-512-2921
and international investors can access the replay by dialing 412-317-6671. The PIN code to access the replay is 13665445.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative
therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, if approved,
will be the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against
Gram-positive, Gram-negative and atypical bacteria. Omadacycline is a new, once-daily oral and intravenous broad-spectrum
antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial
infections, such as acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary
tract infections, and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to
prescribing physicians. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status
by the U.S. Food and Drug Administration for the target indications.
In June 2016, Paratek announced positive efficacy data in a Phase 3 registration study in acute bacterial skin and skin
structure infections (OASIS-1) demonstrating the efficacy and general safety and tolerability of intravenous (IV) to once-daily
oral omadacycline compared to linezolid. In April 2017, Paratek announced positive efficacy data in a Phase 3 registration
study in community-acquired bacterial pneumonia (OPTIC) demonstrating the efficacy and general safety and tolerability of IV to
once-daily oral omadacycline compared to moxifloxacin. In July 2017, Paratek announced positive efficacy data in a Phase 3
registration study in acute bacterial skin and skin structure infections (OASIS-2) demonstrating the efficacy and general safety
and tolerability of oral-only omadacycline compared to linezolid. The Company plans to submit its NDAs in the U.S. as early as the
first quarter of 2018 with an EMA submission later in 2018.
In addition to its Phase 3 program for omadacycline, in November 2016, Paratek reported positive top-line PK proof-of-principle
data in a Phase 1B study in uncomplicated urinary tract infections (UTI). The Company plans to begin enrolling patients in a
proof-of-concept Phase 2 study of omadacycline in acute pyelonephritis, the most common subset of complicated urinary tract
infections, as early as December 2017.
In October 2016, Paratek announced a research agreement with the U.S. Department of Defense to explore the utility of
omadacycline against pathogenic agents causing infectious diseases of public health and biodefense importance including plague and
anthrax.
In April 2017, Paratek Bermuda Ltd., a wholly-owned subsidiary of the Company, and Zai Lab (Shanghai) Co., Ltd., entered into a
License and Collaboration Agreement. Under the terms of the Agreement, the Company granted Zai an exclusive license to develop,
manufacture, and commercialize omadacycline in the People’s Republic of China, Hon Kong, Macau and Taiwan, for all human
therapeutic and preventative uses, other than biodefense.
Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily oral, narrow spectrum
tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the
community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all
ex-U.S. rights. Allergan and Paratek reported positive results from two identical Phase 3 registration studies of sarecycline for
the treatment of moderate to severe acne vulgaris in March 2017. Allergan has publicly announced plans to submit an NDA in the
U.S. in the second half of 2017.
For more information, visit www.paratekpharma.com.
Forward Looking Statements
This press release contains forward-looking statements including statements related to our overall strategy, product
candidates, clinical studies, prospects, potential and expected results, including statements about the timing of advancing
omadacycline and otherwise preparing for clinical studies, the timing of enrollment in our clinical studies and our reporting of
the results of such studies, the potential for omadacycline to serve as an empiric monotherapy treatment option for patients
suffering from ABSSSI, CABP, UTI, and other bacterial infections when resistance is of concern, the prospect of omadacycline
providing broad-spectrum activity, and our ability to obtain regulatory approval of omadacycline All statements, other than
statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as
"advancing," "believe," "expect," "well positioned," "look forward," "anticipated," "continued," and other words and terms of
similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and
uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections
disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our
actual results and the timing of events could differ materially from those included in such forward-looking statements as a result
of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual
Report on Form 10-K for the year ended December 31, 2016, and our other filings with the Securities and Exchange Commission.
We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained
herein.
CONTACTS: Media Relations: Michael Lampe (484) 575-5040 michael@scientpr.com Investor Relations: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568
